Gut bacteria joins fight against aggressive lung cancer

NCT ID NCT06943235

Summary

This study is testing whether adding probiotics (beneficial bacteria) to a combination of high-dose radiation, chemotherapy, and an immunotherapy drug called adebrelimab can better control limited-stage small cell lung cancer. It will involve 60 patients to see if this approach helps keep the cancer from growing or spreading for longer and is safe. The main goal is to see if patients are cancer-free one year after treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

Conditions

Explore the condition pages connected to this study.